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Abstract
Background: Our study was aimed to evaluate the risk of a selected non-motor symptom, namely rapid eye
movement behavior disorder (RBD) symptoms, among patients with newly diagnosed Parkinson disease compared
with health controls.
Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for meta-analysis
and Cochrane manual were followed. Studies on RBD symptoms and PD were searched using PubMed, Embase, Web of
Science and Cochrane library databases. All studies were published before August 3rd, 2016. Eligible studies were those
that reported a prevalence of RBD symptoms among newly diagnosed PD and health control. Pooled odds ratios (ORs)
with 95% confidence intervals (CIs) were calculated by random-effected models. Heterogeneity across studies was
assessed using Cochran Q and I2 statistics.
Results: We identified eight studies including 2462 PD patients and 3818 health controls. The overall prevalence of RBD
symptoms in PD was 582/2462 (23.6%) compared to 131/3818 (3.4%) in control. And the pooled OR was 5.69 (95% CI 3.
60 to 9.00; p = 0.001) with a moderate heterogeneity I2 = 70.5%. After excluding the study of low weight, the overall
polled OR was 3.54 (95% CI 2.77 to 4.52; p < 0.00001) and the heterogeneity was completely eliminated (I2 = 0%).
Conclusions: RBD symptoms are common non-motor symptoms of PD, and people with PD are at a higher risk of
developing RBD. Further studies are needed to understand the natural history of RBD symptoms in PD and its etiological
and clinical implications.
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Background
Parkinson’s disease (PD) is the second most prevalent
neurodegenerative disease with a prevalence of approxi-
mately 0.4% in people aged 65 and older, and it increases
with age [1]. Apart from motor dysfunction, PD patients
also suffer from a variety of non-motor symptoms (NMS),
such as hyposmia, rapid eye movement sleep behavior
disorder (RBD), constipation and depression [2]. However,
certain non-motor symptoms might precede the develop-
ment of motor symptoms by many years [3]. RBD is
characterized by the loss of normal atonia of REM sleep,
resulting in an apparent acting out of dream content [4].
It has been reported that RBD as a premotor feature
occurred in 38% of patients who developed PD in a mean
interval of 3.5 years after a RBD diagnosis [5]. The pres-
ence of RBD in prodromal PD is consistent with the Braak
hypothesis which implies that it may occur as the result of
underlying Lewy pathogenesis at lower brainstem before
invading substantial nigra [6]. However, reported preva-
lence of RBD in PD patients varies greatly from 20 to 72%
[7], and the prevalence of probable RBD was estimated to
be about 4.9% in the general population [8]. To date, no
meta-analysis has examined the magnitude of risk associ-
ated with PD and the development of RBD. We therefore
conducted a meta-analysis to estimate the prevalence of
RBD symptoms among patients with newly diagnosed PD
compared with health controls.
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We conducted a systematic search of original published
studies that reported the prevalence of RBD symptoms in
PD and health controls. Two researchers (JZ and CYX) inde-
pendently undertook a search on PubMed, Web of Science,
Embase and Cochrane library databases for literature pub-
lished in English, which were published before August 3rd,
2016. We combined medical subject heading (MeSH) terms
including “PD, RBD” and text terms including “Idiopathic
Parkinson's Disease, Lewy Body Parkinson Disease, Primary
Parkinsonism, Parkinsonism, Primary Parkinson Disease,
Paralysis Agitans” and “REM Behavior Disorder, Rapid Eye
Movement Sleep Behavior Disorder” as our search strategy.
Restrictions were made to observational epidemiologic
studies involving humans. Titles and abstracts were screened
for their suitability. Articles whose abstracts did not report
on RBD symptoms and PD were excluded. Full articles were
then obtained and reviewed to determine suitability for
inclusion or exclusion. Differences of opinion between the
researchers were resolved through discussion. The reference
lists of all full articles were included. In addition, references
from reviews that were identified in the original study, were
hand-searched as additional articles, and then subjected to
the same filtering process as described above.
Inclusion criteria
Published articles that met the following criteria were in-
cluded: 1) observational studies with a cohort, case-control
or cross-section design; 2) cases where patients were diag-
nosed with PD according to standard clinical criteria, such
as UK Parkinson’s Disease Society Brain Bank Criteria [9];
3) controls were drawn from the same population as cases;
4) controls were healthy or had no history of neurological
disease; 5) RBD symptoms in controls were assessed over
the same time period as patients; 6) RBD symptoms were
assessed by means of polysomnography (PSG), or struc-
tured questionnaire, or coded in patient medical records or
medication used to treat RBD symptoms and 7) original
data were reported.
Exclusion criteria
We excluded studies for the following reasons: 1) studies
in the form of case report, review, conference abstracts,
or letters that did not report new data; 2) studies that
only provided risk estimates such as relative risk without
numbers of individuals; 3) duplicate populations; 4) did
not provide adequate details of the control group; 5) did
not report sufficient data to calculate risk estimates; and
6) non-English publications or non-human studies.
Data extraction
Two researchers (JZ and CYX) reviewed all abstracts inde-
pendently either to determine the eligibility criteria or for
examining the appropriateness on the research issue. Data
were compared and disagreements were resolved by a
consensus. The following information was extracted from
each study, and included: name of first author, year of
publication, study data, study design, sample size, patient
mean age, geographical region, RBD symptoms assessment
method and other relevant study characteristics. Finally,
studies were assessed for quality using the Newcastle-
Ottawa Scale (NOS) [10].
Statistical analysis
Measures of effect were combined using standard meta-
analysis methods. We used the odds ratio (OR) with a
95% confidence interval (CI) as the metric of risk, using
the random effects model. Heterogeneity across studies
was evaluated by the Cochrane’s Q statistic and by I2 test,
the percentage of I2 around 25, 50 and 75% mean low,
medium and high heterogeneity [11]. A sensitivity analysis
was conducted to evaluate the source of heterogeneity.
Publication bias was assessed using the Egger test and a
funnel plot [12]. Statistical analysis was undertaken in
STATA (version 12.0; StataCorp, Corporation, College
Station, TX, USA) and RevMan (version 5.1; the Cochrane
Collaboration, Oxford, United Kingdom).
Results
The literature search yielded 749 records (include three
studies from hand searching of references) after duplicates
were removed. Of these, 673 records were excluded on the
basis of their title and abstract. Review of the remaining 76
full articles led to 68 exclusions based on criteria described
above. Finally, eight studies fulfilled our inclusion criteria
and were included in our meta-analysis with a total number
of 2462 PD patients and 3818 health controls (Fig. 1).
Of these, seven studies were case-control designs [14–20],
and one was a cross-sectional study [21]. Most of the studies
were conducted in Europe and North America [15, 16, 18–
21], with one conducted in Asia [14], and one study con-
ducted in Africa [17]. We divided the eight studies into two
subgroups according to different RBD assessment methods
described in the articles. If RBD was diagnosed with ICD
(International classification of disease), RBD-SQ (RBD-
screening questionnaire) or PSG, the symptom was defined
as definite RBD [14, 16, 21]. If RBD was diagnosed with
NMS-SQ, self-made Questionnaire or MSQ (Mayo Sleep
Questionnaire), the symptom was defined as probable RBD
[15, 17–20]. Summary characteristics for all included studies
are provided in (Table 1). With NOS quality criteria, all stud-
ies scored ≥ 7/9 and six of the included studies scored 8/9.
The overall prevalence of RBD symptoms in PD was
582/2462 (23.6%) compared to 131/3818 (3.4%) in
control. And the pooled OR was 5.69 (95% CI 3.60 to
9.01) with a moderate heterogeneity (I2 = 70.6%; p =
0.001) (Fig. 2). Subgroup analysis according to different
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diagnostic methods showed that the pooled OR for
“Probable RBD” group was 6.08 (95% CI 3.87 to 11.93)
with evidence of moderate heterogeneity (I2 = 58.2%; p =
0.048) and 4.14 for “Definite RBD” (95% CI 2.21 to 7.78)
with medium heterogeneity (I2 = 68.7%; p = 0.041). After
excluding the study of low weight [15, 19, 21], the
overall polled OR was 3.54 (95% CI 2.77 to 4.52) and the
heterogeneity was completely eliminated (I2 = 0%; p <
0.00001). Visual inspections of the funnel plot revealed a
little asymmetry (Fig. 3) and significant publication bias
Fig. 1 PRISMA [13] flow chart of literature review and data abstraction
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was detected from results of the statistical test (Begg
test: p = 0.019; Egger test: p = 0.011).
The results of our meta-analysis show a definite associ-
ation between PD and RBD symptoms. Since studies in-
cluded were of different study design, population bases and
methods of exposure ascertainment, the heterogeneity
across the studies was high. To identify studies that may
have contributed to the pooled heterogeneity, we removed
each of the eight studies (one study at a time) and exam-
ined the magnitude and direction of the polled relative risk
(RR) after the removal of each study. This approach was re-
peated until the I2 statistic was deemed zero. Three studies
[15, 19, 21] were identified as the source of heterogeneity in
this study. After removing all of those studies, the polled
OR was 3.54 (95% CI 2.77 to 4.52; I2 statistic = 0%), and the
association between PD and the risk of developing RBD
symptoms was still statistically significant.
Discussion
Our systematic review and meta-analysis offers a confirm-
ation of the association between PD and a subsequent diag-
nosis of RBD. The pooled prevalence of RBD symptoms in
PD and control is 23.6 vs. 3.4%, and the patients who had
symptoms of PD carried a 3.60 to 9.00-fold increased risk
for developing RBD compared to health controls. It is
important to quantify the magnitude of the association
between PD and subsequent RBD symptoms, as this may
underpin efforts to identify higher risk participants for entry
to interventional studies with neuroprotective aims.
REM sleep behavior disorder (RBD) is a parasomnia dis-
order characterized by repeated episodes of dream enact-
ment behavior and REM sleep without atonia (RSWA)
during polysomnography (PSG) [22]. The main suspected
mechanism of RBD is a lesion in the REM sleep atonia
system, which is mainly located in the pontomedullary
area [23]. RBD is important as a valuable preclinical
marker of PD. Firstly, idiopathic RBD converted to neuro-
degenerative disease at a high rate ranging from 28 to 82%
[24–27]. Secondly, many potential early marker of PD are
significantly abnormal in iRBD, such as decreased striatal
dopamine transporter binding, marked EEG slowing,
substantial nigra hyperechogenicity and impaired olfaction
[28–30]. Lastly, RBD is also associated with some specific
PD phenotypes. It is known that age, gender, disease
duration, motor disability, dopaminergic drug, motor
phenotype, cognition, and autonomic dysfunction are
different in PD patients with RBD compared to PD
patients without the disorder [7].
Fig. 2 Forest plot demonstrating increased RBD risk in those with PD as compared with those control (CI, confidence interval; OR, odds ratio)
Fig. 3 Funnel plot assessing publication bias in the study of RBD
association with PD
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Our study demonstrates that there is potential for publi-
cation bias based on the funnel plot and significant publica-
tion bias was detected from results of the statistical test
(Begg test: p = 0.019; Egger test: p = 0.011). This might re-
sult in an overestimation of the association between PD
and the risk of RBD symptoms. Considering that we only
included eight studies which were assessed via means of
the NOS, and all studies included in the main analysis had
scores ≥ 7/9, we can conclude that the risk estimate that re-
sulted from this analysis may also be viewed as a fairly strict
estimate, and a result of the pooling of data from only the
highest quality studies.
Similar to any other meta-analysis of observational studies,
our study is subject to several limitations. First, we limited
our search to publications in English and therefore might
have missed a small number of relevant publications.
Second, recall bias may affect the quality of information
retrieved from participants in case-control studies and the
assessment of RBD symptoms may vary from one study to
another. Third, more high quality and large sample sizes ob-
servation studies estimating the risk of RBD symptoms in
PD should be included in order to avert the publication bias.
Conclusion
In conclusion, despite these limitations, we pooled data
from 6280 people across eight studies to provide a consoli-
dated risk that estimated relating PD to the development of
RBD symptoms. Most of the evidence was of the highest
quality and the conclusion was considered robust. Further
prospective research is needed to examine the presence of
RBD symptoms and its relationship to PD, in order to bet-
ter understand the etiology and natural history of PD.
Abbreviations
MSQ: Mayo sleep questionnaire; NMS: Non-motor symptoms;
NOS: Newcastle-Ottawa Scale; OR: Odds ratio; PD: Parkinson’s disease;
PSG: Polysomnography; RBD: Rapid eye movement behavior disorder;
RSWA: REM sleep without atonia
Acknowledgements
We thank all the authors of the included studies, and especially thank Pei
Huang and Dun-Hui Li for study coordination.
Funding
This work was supported by grants from National Natural Science Fund
(81071024, 81171202, 81471287, 81371407 and 81228007), Shanghai
Shuguang Program (11SG20), and Shanghai Municipal Education
Commission—Gaofeng Clinical Medicine Grant Support (20152201).
Availability of data and materials
All data generated or analyzed during this study are included in this
published article.
Authors’ contributions
JL designed the whole study and gave suggestions on revising the article.
JZ and CYX searched and selected the studies, JZ and CYX analyzed the
data, drafted and revised the article. JZ prepared figures. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interest.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was approval by the Institutional Ethics Committee of Shanghai
Jiao Tong University School of Medicine ((2011) ethics committee No.13).
Written consent form to use their clinical data was obtained from each
participant.
Received: 19 September 2016 Accepted: 11 January 2017
References
1. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease:
a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–90.
2. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J,
Marek K, Litvan I, Lang AE, et al. MDS clinical diagnostic criteria for
Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.
3. Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, Ziemssen
T. Identifying prodromal Parkinson’s disease: pre-motor disorders in
Parkinson’s disease. Mov Disord. 2012;27(5):617–26.
4. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral
disorders of human REM sleep: a new category of parasomnia. Sleep. 1986;
9(2):293–308.
5. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a
parkinsonian disorder in 38% of 29 older men initially diagnosed with
idiopathic rapid eye movement sleep behaviour disorder. Neurology. 1996;
46(2):388–93.
6. Braak H, Del Tredici K, Rüb U, de Vos RA, Steur ENJ, Braak E. Staging of brain
pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;
24(2):197–211.
7. Kim YE, Jeon BS. Clinical implication of REM sleep behavior disorder in
Parkinson’s disease. J Parkinsons Dis. 2014;4(2):237–44.
8. Ma JF, Hou MM, Tang HD, Gao X, Liang L, Zhu LF, Zhou Y, Zha SY, Cui SS,
Du JJ, et al. REM sleep behavior disorder was associated with Parkinson’s
disease: a community-based study. BMC Neurol. 2016;16:123.
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of
idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J
Neurol Neurosurg Psychiatry. 1992;55(3):181–4.
10. GA Wells BS, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised
studies in meta-analyses. Canada: Department of Epidemiology and
Community Medicine UoO; 2000.
11. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis.
Stat Med. 2002;21(11):1539–58.
12. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected
by a simple, graphical test. BMJ. 1997;315(7109):629–34.
13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke
M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate health care
interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
14. Wu Y-H, Liao Y-C, Chen Y-H, Chang M-H, Lin C-H. Risk of premotor
symptoms in patients with newly diagnosed PD: a nationwide, population-
based, case-control study in Taiwan. PLoS One. 2014;10(6):e0130282.
15. Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R, Mas
N, Hofeneder D, Brücke T, Bayés A, et al. The onset of nonmotor symptoms
in parkinson’s disease (the onset pd study). Mov Disord. 2015;30(2):229–37.
16. Baig F, Lawton M, Rolinski M, Ruffmann C, Nithi K, Evetts SG, Fernandes HR,
Ben-Shlomo Y, Hu MT. Delineating nonmotor symptoms in early Parkinson’s
disease and first-degree relatives. Mov Disord. 2015;30(13):1759–66.
17. Trinh J, Amouri R, Duda JE, Morley JF, Read M, Donald A, Vilarino-Gueell C,
Thompson C, Tu CS, Gustavsson EK, et al. A comparative study of
Parkinson’s disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism.
Neurobiol Aging. 2014;35(5):1125–31.
18. Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O’Brien JT, Brooks DJ, Barker
RA, Burn DJ. The spectrum of nonmotor symptoms in early Parkinson
disease. Neurology. 2013;80(3):276–81.
19. Adler CH, Hentz JG, Shill HA, Sabbagh MN, Driver-Dunckley E, Evidente VG,
Jacobson SA, Beach TG, Boeve B, Caviness JN. Probable RBD is increased in
Parkinson’s disease but not in essential tremor or restless legs syndrome.
Parkinsonism Relat Disord. 2011;17(6):456–8.
Zhang et al. BMC Neurology  (2017) 17:23 Page 5 of 6
20. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P,
Brown RG, Koller W, Barone P, MacPhee G, et al. International multicenter
pilot study of the first comprehensive self-completed nonmotor symptoms
questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord.
2006;21(7):916–23.
21. Sixel-Doering F, Trautmann E, Mollenhauer B, Trenkwalder C. Rapid Eye
movement sleep behavioral events: a new marker for neurodegeneration in
early Parkinson disease? Sleep. 2014;37(3):431.
22. Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and
neurodegenerative disease. JAMA Neurol. 2015;72(6):707–12.
23. Chen MC, Yu H, Huang Z-L, Lu J. Rapid eye movement sleep behavior
disorder. Curr Opin Neurobiol. 2013;23(5):793–8.
24. Postuma RB, Gagnon JF, Vendette M, Montplaisir JY. Markers of
neurodegeneration in idiopathic rapid eye movement sleep behaviour
disorder and Parkinson’s disease. Brain. 2009;132(Pt 12):3298–307.
25. Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M,
Sanchez-Valle R, Vilaseca I, Lomena F, Vilas D, et al. Neurodegenerative
disease status and post-mortem pathology in idiopathic rapid-eye-
movement sleep behaviour disorder: an observational cohort study. Lancet
Neurol. 2013;12(5):443–53.
26. Postuma RB, Iranzo A, Hogl B, Arnulf I, Ferini-Strambi L, Manni R, Miyamoto
T, Oertel W, Dauvilliers Y, Ju YE, et al. Risk factors for neurodegeneration in
idiopathic rapid eye movement sleep behavior disorder: a multicenter
study. Ann Neurol. 2015;77(5):830–9.
27. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a
parkinsonian disorder or dementia in 81% of older men initially diagnosed
with idiopathic rapid eye movement sleep behavior disorder: a 16-year
update on a previously reported series. Sleep Med. 2013;14(8):744–8.
28. Iranzo A, Lomena F, Stockner H, Valldeoriola F, Vilaseca I, Salamero M,
Molinuevo JL, Serradell M, Duch J, Pavia J, et al. Decreased striatal
dopamine transporter uptake and substantia nigra hyperechogenicity as risk
markers of synucleinopathy in patients with idiopathic rapid-eye-movement
sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol.
2010;9(11):1070–7.
29. Fantini ML, Gagnon JF, Petit D, Rompre S, Decary A, Carrier J, Montplaisir J.
Slowing of electroencephalogram in rapid eye movement sleep behavior
disorder. Ann Neurol. 2003;53(6):774–80.
30. Fantini ML, Postuma RB, Montplaisir J, Ferini-Strambi L. Olfactory deficit in
idiopathic rapid eye movements sleep behavior disorder. Brain Res Bull.
2006;70(4–6):386–90.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Zhang et al. BMC Neurology  (2017) 17:23 Page 6 of 6
